Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. The company was founded in 2011 and is headquartered in Beijing, China.
Stock data | 2024 | Change |
---|---|---|
Price | $1.46 | N/A |
Market Cap | $608.20M | N/A |
Shares Outstanding | 416.20M | N/A |
Employees | 0 | N/A |